logo

For the Inventor, By the Inventor

Waltham, MA, United States of America

Charlotte McDonagh

This inventor holds 13 USPTO granted patents and 1 published patent application, primarily in Monoclonal Antibodies. Top assignees: Seattle Genetics, Inc., Merrimack Pharmaceuticals, Inc., Seagen Inc.. Active years: 2011-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Charlotte McDonagh. Retrieved from https://idiyas.com/inventor/charlotte-mcdonagh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 13 

% Patents Active = 92.3

Average Co-Inventor Count = 3.1

ph-index = 10

Forward Citations = 329(Granted Patents)


Location History:

  • Winchster, MA (US) (2013)
  • Winchester, MA (US) (2012 - 2016)
  • Seattle, WA (US) (2011 - 2017)
  • Waltham, MA (US) (2011 - 2022)

Company Filing History:

goldMedal10 out of 132 
 
Seattle Genetics, Inc.
 patents
silverMedal2 out of 54 
 
Merrimack Pharmaceuticals, Inc.
 patents
bronzeMedal1 out of 66 
 
Seagen Inc.
 patents

Years Active: 2011-2022

Loading Chart...
Areas of Expertise:
CD19 Binding Agents
CD70 Binding Agents
Combination Therapies
Human Serum Albumin Linkers
Variant Target Binding Agents
Anti-ERBB3 Agents
Humanized Antibodies
Therapeutic Uses
13 patents (USPTO):Explore Patents
1. 11331394 - CD19 binding agents and uses thereof (2022-05-17),
2. 9919061 - CD19 binding agents and uses thereof (2018-03-20),
3. 9701752 - Humanized anti-CD70 binding agents and uses thereof (2017-07-11),
4. 9428585 - Humanized anti-CD70 binding agents and uses thereof (2016-08-30),
5. 9345766 - Combination therapies comprising anti-ERBB3 agents (2016-05-24),
6. 9073993 - CD19 binding agents and uses thereof (2015-07-07),
7. 8927694 - Human serum albumin linkers and conjugates thereof (2015-01-06),
8. 8562987 - Humanized anti-CD70 binding agents and uses thereof (2013-10-22),
9. 8455622 - Variant target binding agents and uses thereof (2013-06-04),
10. 8257706 - CD30 binding agents and uses thereof (2012-09-04),
11. 8242252 - CD19 binding agents and uses thereof (2012-08-14),
12. 8067546 - Humanized anti-CD70 binding agents and uses thereof (2011-11-29),
13. 7968687 - CD19 binding agents and uses thereof (2011-06-28),

Title: The Innovative Contributions of Charlotte McDonagh

Introduction

Charlotte McDonagh is a prominent inventor based in Waltham, MA (US), known for her significant contributions to the field of biotechnology. With a total of 13 patents to her name, she has made remarkable strides in developing innovative solutions for medical treatments.

Latest Patents

Among her latest inventions are the CD19 binding agents and their uses. This invention relates to CD19 binding agents and methods of using such agents for treating diseases. Her work in this area showcases her commitment to advancing medical science and improving patient outcomes.

Career Highlights

Charlotte has had a successful career, working with notable companies such as Seattle Genetics, Inc. and Merrimack Pharmaceuticals, Inc. Her experience in these organizations has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Throughout her career, Charlotte has worked alongside esteemed colleagues, including Paul J. Carter and Charles G. Cerveny. These collaborations have further enriched her work and expanded the impact of her inventions.

Conclusion

Charlotte McDonagh's innovative spirit and dedication to her field have led to significant advancements in biotechnology. Her contributions, particularly in the development of CD19 binding agents, highlight her role as a leading inventor in the industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…